预约演示
更新于：2026-03-10
Epinastine Hydrochloride
盐酸依匹斯汀
更新于：2026-03-10
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C16H16ClN3 |
InChIKeyVKXSGUIOOQPGAF-UHFFFAOYSA-N |
CAS号108929-04-0 |
关联
52
项与 盐酸依匹斯汀 相关的临床试验CTR20254779
盐酸依匹斯汀片在中国健康试验参与者中的单中心、随机、开放、单次给药、两制剂、两序列、两周期、双交叉、空腹及餐后状态下的生物等效性试验
CTR20252460
盐酸依匹斯汀片在中国健康研究参与者中的单中心、随机、开放、单次给药、两制剂、两序列、两周期、双交叉、空腹及餐后状态下的生物等效性试验
CTR20243732
盐酸依匹斯汀片在健康受试者中的单中心、随机、开放、单次给药、两制剂、两序列、两周期、双交叉、空腹及餐后状态下的生物等效性研究
100 项与 盐酸依匹斯汀 相关的临床结果
登录后查看更多信息
100 项与 盐酸依匹斯汀 相关的转化医学
登录后查看更多信息
100 项与 盐酸依匹斯汀 相关的专利（医药）
登录后查看更多信息
225
项与 盐酸依匹斯汀 相关的文献（医药）2025-11-01NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
Population modeling of pharmacokinetic variability of epinastine, a histamine H1 receptor antagonist, according to cytochrome P450 2D6 phenotypic polymorphisms
Article
作者: Jeong, Seung-Hyun ; Jang, Ji-Hun
Although epinastine has been actively used in clinical practice for treatment of allergic diseases, attempts to interpret and quantify pharmacokinetic (PK) diversity within population have been very limited. In particular, there have been no studies on population-pharmacokinetic (pop-PK) modeling of epinastine focusing on genetic factors. The primary objective of this study was to quantitatively interpret the PK variability of epinastine according to phenotypic polymorphisms of cytochrome P450 (CYP) 2D6 in Korean population and to construct a new pop-PK model considering such polymorphisms. The bioequivalence PKs, physiologic and biochemical parameter analyses, and CYP2D6 genotyping results performed in 26 healthy Korean males were used in this study. The pop-PKs of epinastine were described by the first-order oral absorption and distribution between central and peripheral compartments, and elimination from the central compartment as the basic model structure. The covariate reflection of physiologic and biochemical parameters was not valid. Conversely, CYP2D6 phenotypic polymorphisms were explored as valid covariates for clearance from the central compartment (CLc/F). Compared to extensive-metabolizers (EMs), the decreases in typical CLc/F values in intermediate-metabolizers (IMs) and poor-metabolizers (PMs) were estimated as 28.06% and 49.48%, respectively. As a result of pop-PK model simulation, the serum concentrations of epinastine at steady-state significantly increased from CYP2D6 EMs to IMs and PMs. The degree of increase was 1.97 (in PMs compared to EMs) and 1.39 (in IMs compared to EMs) based on the corresponding value of 50% of the group. This study provides a new perspective on the quantitative interpretation of PK changes for epinastine according to CYP2D6 genotypic factors and is expected to be an important bridgehead for improving clinical efficacy and safety through precision pharmacotherapy.
2025-07-16BIOLOGICAL & PHARMACEUTICAL BULLETIN
Second-Generation H<sub>1</sub>-Receptor Antagonists, Mequitazine, Azelastine and Desloratadine Activate Caspase-8, Caspase-3, and Gasdermin E and Induce Cell Death Showing Pyroptotic-Like Features in Macrophages at Excessively High Concentrations
Article
作者: Ito, Akane ; Nakajima, Mitsunari ; Sawamoto, Atsushi ; Okuyama, Satoshi
Histamine H1 receptor (H1R) is expressed in various cells, including neurons, smooth muscle cells, hepatocytes, T and B cells, neutrophils, dendritic cells, monocytes, and macrophages. Antagonists that target the H1R are used to relieve the symptoms of allergy and inflammation. Here, we examined the inflammation-modulating and cell death-inducing effects of 10 second-generation H1R antagonists on mouse intraperitoneal macrophages, which include ketotifen, mequitazine, azelastine, oxatomide, epinastine, bepotastine, fexofenadine, loratadine, levocetirizine, and desloratadine, to assess an anticipated adverse reaction. Three of these antagonists, namely, mequitazine, azelastine, and desloratadine, induced the secretion of interleukin-1α (IL-1α), a marker of pyroptosis and an inflammatory cytokine, from the macrophages at excessively high concentrations, while reducing the secretion of another inflammatory cytokine, IL-6. We found that the macrophages treated with the 3 antagonists showed pyroptotic-like, but not apoptotic-like, morphology and died. Western blotting analysis revealed that caspase-8, caspase-3, and gasdermin E (GSDME), but not gasdermin D, were cleaved and activated in the macrophages. These results suggest that second-generation H1R antagonists such as mequitazine, azelastine, and desloratadine induce pyroptotic-like cell death accompanied by caspase-8, caspase-3, and GSDME activation in macrophages.
2025-06-26Cureus Journal of Medical Science
Topical Innovation: A Report on Epinastine Eyelid Cream for Patients With Mild Atopic Keratoconjunctivitis
Article
作者: Mimura, Tatsuya ; Fukagawa, Kazumi
Allergic conjunctivitis is a common ocular disorder that significantly impacts patients' quality of life. Conventional treatments, primarily anti-allergic and corticosteroid eye drops, require frequent administration, posing adherence challenges. Poor compliance is a major barrier to effective management, particularly in pediatric and elderly patients. Recently, a novel 0.5% epinastine topical eyelid cream, designed for once-daily application, has been introduced as an alternative treatment. However, no clinical reports for atopic keratoconjunctivitis have assessed its efficacy and safety in real-world practice. This study presents a clinical report on the use of 0.5% epinastine topical eyelid cream in three patients with allergic conjunctivitis and atopic dermatitis, evaluating its therapeutic efficacy, adherence, and tolerability. We examined three cases of allergic conjunctivitis associated with atopic dermatitis treated with once-daily 0.5% epinastine topical eyelid cream. Clinical outcomes were assessed using an allergic conjunctivitis severity score based on objective findings. Adherence and safety were also evaluated. All patients exhibited rapid symptom improvement, with significant reductions in ocular pruritus, conjunctival hyperemia, and eyelid dermatitis. By week four, allergic conjunctivitis severity scores had improved markedly in all cases (from baseline scores of 8-13 to 3-6). No adverse effects or treatment discontinuations were observed. Notably, all patients reported high adherence and ease of use, with reduced reliance on eye drops. This case series provides the clinical evidence supporting the efficacy and tolerability of 0.5% epinastine topical eyelid cream for allergic conjunctivitis, particularly in patients with coexisting atopic dermatitis. The once-daily application may enhance adherence and serve as a viable alternative or adjunct to conventional eye drops. Further large-scale studies are warranted to validate these findings.
100 项与 盐酸依匹斯汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 变应性结膜炎 | 日本 | 2013-09-20 | |
| 季节性过敏性结膜炎 | 奥地利 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 比利时 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 捷克 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 丹麦 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 法国 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 德国 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 希腊 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 匈牙利 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 爱尔兰 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 意大利 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 卢森堡 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 荷兰 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 波兰 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 葡萄牙 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 斯洛伐克 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 西班牙 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 瑞典 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 英国 | 2003-03-04 | |
| 银屑病 | 中国 | 2000-06-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 季节性过敏性鼻炎 | 临床3期 | - | 2007-12-18 | |
| 特应性皮炎 | 临床3期 | - | 2001-06-01 | |
| 常年性变应性鼻炎 | 临床3期 | - | 2000-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| - | 30 | 壓鬱遞製製襯鬱夢繭膚(鏇壓壓膚構蓋製遞願積): p = < 0.0001 更多 | 积极 | 2024-09-01 | |||
安慰剂 | |||||||
临床3期 | 87 | (Epinastine (DE-114) Ophthalmic Solution) | 壓遞觸選膚窪膚遞顧壓(遞獵鏇鹽壓鏇鑰窪選範) = 鏇糧夢獵積膚獵觸廠鏇 鹽範淵壓艱餘夢築襯餘 (築窪窪襯齋選願窪襯夢, 0.1) 更多 | - | 2014-11-05 | ||
Placebo (Placebo Ophthalmic Solution) | 壓遞觸選膚窪膚遞顧壓(遞獵鏇鹽壓鏇鑰窪選範) = 襯簾築獵簾憲淵積繭衊 鹽範淵壓艱餘夢築襯餘 (築窪窪襯齋選願窪襯夢, 0.1) 更多 | ||||||
临床3期 | 130 | 鑰餘選糧鬱繭積鹹蓋餘(艱膚選蓋顧構簾淵壓遞) = 鹽構範簾範網顧網鑰衊 鑰鏇衊願蓋築網網繭壓 (觸齋選膚蓋願窪遞範觸, 0.1) 更多 | - | 2014-09-23 | |||
临床4期 | 79 | (Elestat) | 鑰鬱窪選廠衊膚鏇簾願(觸糧製選鬱窪獵網衊壓) = 夢廠衊鑰齋範窪壓壓簾 鹹積鏇繭獵壓鹽窪鹽糧 (鹽鑰繭觸獵獵觸積餘構, 1.36) 更多 | - | 2009-05-27 | ||
(Pataday) | 鑰鬱窪選廠衊膚鏇簾願(觸糧製選鬱窪獵網衊壓) = 製鹽鹽獵憲範糧窪餘鑰 鹹積鏇繭獵壓鹽窪鹽糧 (鹽鑰繭觸獵獵觸積餘構, 1.07) 更多 | ||||||
N/A | - | - | Epinastine HCl 0.05% | 顧衊範憲鏇艱壓糧憲顧(廠鹹鑰遞廠醖餘遞窪憲) = primarily colds/URI, was the most frequent AE reported in 5.0% of epinastine subjects and 8.3% of vehicle subjects 鏇膚醖醖鬱獵夢廠鹹衊 (淵襯鬱壓網積鹽範築壓 ) | 积极 | 2003-05-01 | |
Vehicle |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用